Surgeons need to adapt to evolving strategies for hepatocellular carcinoma (HCC) that prioritize biological insights and dynamic eligibility criteria.
- Curative treatments offer optimal long-term outcomes, yet 5-year recurrence rates remain at about 70%.
- New methods in immunogenomic profiling and liquid biopsy enhance patient selection beyond traditional staging.
These advances enable personalized surgical strategies and improve outcomes.
- Innovations in perioperative immunotherapy and graft preservation techniques may further reduce recurrence risk and broaden curative options.
Review by Malik AK, Geh D (…) White SA et 3 al. in Nat Rev Gastroenterol Hepatol
© 2025. Springer Nature Limited.